900 million antibacterial drugs will welcome the third review! Hebei pharmaceutical companies "rush to fight" Baiyunshan, Sinopharm

Pharmaceutical Network September 23rd, September 22nd, CDE official website shows that North China Pharmaceuticals Hebei Huamin Pharmaceuticals' cephalosporineparticles to copy 3 categories of filing applications for listing was accepted.
meters intranet data show that in 2019, China's public medical institutions terminal cephalosporineparticle sales of more than 900 million yuan, of which, Baiyunshan Pharmaceutical Factory market share of more than 60%, ranked first.
the evaluation of the technology, only Baiyunshan Pharmaceutical General Plant and Guopharma Zhijun (Shenzhen) Pharmaceuticals to supplement the application was approved for evaluation.
data show that cephalosporinsis the first third generation of oral cephalosporins, clinically suitable for cephalosporins -sensitive streptococcus genus (except enterococcus), pneumococcal, gonorrhoe, catastran, E. coli, Bacterial infectious diseases caused by Clebobacteria genus, Sarepsis genus, Bacillus deformation genus and influenza bacteria, including bronchitis, bronchial dilation (at the time of infection), secondary infection of chronic respiratory infections, pneumonia, gallbladderitis, bilebaritis, scarlet fever, etc.
In recent years, China's public medical institutions terminal cephalosporine particle sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal head Sporesparticle sales of more than 900 million yuan, the main production enterprises have Baiyunshan Pharmaceutical Factory, Guopharma Zhijun (Shenzhen) Pharmaceuticals and other 8, of which, Baiyunshan Pharmaceutical General Factory market share is the largest, more than 60%;
source: Mi Net one-click search consistency evaluation, only Baiyunshan Pharmaceutical General Plant and Guopharma Zhijun (Shenzhen) Pharmaceuticals to supplement the application was approved.
At present, Chengdu Bett Pharmaceuticals' consistency evaluation supplementary application in the review and approval (in the drug review center), Zhejiang Jutai Pharmaceuticals and Jinhong Pharmaceuticals with imitation 3 categories of declaration listed in the review and approval (in the drug review center), after approval will be treated as a review.
.